Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Blood Cancer J. 2022 Nov 16;12(11):156. doi: 10.1038/s41408-022-00743-0.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Janus Kinase 2 / genetics
  • Mutation
  • Primary Myelofibrosis* / complications
  • Primary Myelofibrosis* / genetics
  • Thrombosis* / genetics

Substances

  • JAK2 protein, human
  • Janus Kinase 2